Natera to unveil SAGITTARIUS Phase III data at ESMO 2026 showing Signatera changed treatment plans for one in three colon cancer patients

Natera will present SAGITTARIUS Phase III data at ESMO 2026 showing Signatera results changed treatment plans for one in three colon cancer patients, of whom 87% de-escalated on MRD negativity.

Detected & updated continuously · Source: Nebula